Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
In Guru Portfolios
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
| Steven Cohen | Point72 Asset Management, L.P. | 0.0% | +0.00% |
| Kenneth Griffin | CITADEL ADVISORS LLC | 0.0% | +0.00% |
About
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase III clinical trials and is designed to treat peanut allergies in children aged 4 to 11, as well as adolescents and adults. The company is also advancing Viaskin Milk, which is in Phase I/II clinical trials for Immunoglobulin E (IgE)-mediated cow's milk protein allergy (CMPA). Beyond this, its pipeline includes Viaskin Egg, a preclinical product for hen's egg allergy, and a booster vaccine for Bordetella pertussis. Further early-stage research programs are exploring a vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. DBV is collaborating with Nestlé Health Science on MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE mediated CMPA in infants and toddlers. Founded in 2002, DBV Technologies S.A. is headquartered in Montrouge, France.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of DBV.PA is 3.70 and suggests 60.5% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in